Clinical Performance Evaluation of the Polymerase Chain Reaction (PCR)-Based Cobas CT/NG/MG Test for Use on the Cobas Liat System in a Clinical Laboratory Setting and Point-of-Care (POC) Location
This clinical performance evaluation of the Cobas® Liat CT/NG/MG nucleic acid test, conducted in diverse clinical settings across the United States, aimed to address the challenges posed by sexually transmitted infections (STIs) such as Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG). The results highlighted the good clinical performance of the Cobas Liat CT/NG/MG test, particularly in providing rapid lab-quality testing at the point of care for both self- and clinician-collected samples. In clinical settings, the test was identified as a tool to provide rapid testing for CT, NG, and MG infections, offering the potential to minimize the need for empiric treatment. This presents an opportunity to improve clinical outcomes for patients and enhance antimicrobial stewardship. An audio accompaniment to this poster was made available to online participants ADLM 2024.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.